CDMO Avid Bioservices Inc revenue, earnings and financials
For the quarter ended October 31, 2024, Avid Bioservices Inc reported revenue of $33.5M (up 31.8% from a year earlier), net income of −$17.4M and diluted EPS of −$0.27; over the last four quarters revenue was $150M and net income −$152M; for the fiscal year ended April 2024 revenue was $140M, down 6.3% on the year before.
CDMO annual revenue and earnings
- Fiscal year ended Apr 2024: revenue $140M, gross profit $7.32M, operating income −$18.7M, net income −$141M (margin -100.6%), EPS −$2.23
- Fiscal year ended Apr 2023: revenue $149M, gross profit $31.5M, operating income $3.60M, net income $259K (margin 0.2%), EPS $0.00
- Fiscal year ended Apr 2022: revenue $120M, gross profit $36.6M, operating income $15.4M, net income $128M (margin 106.8%), EPS $1.84
CDMO quarterly revenue and earnings
- Quarter ended Oct 31, 2024: revenue $33.5M (up 31.8% year over year), net income −$17.4M, EPS −$0.27
- Quarter ended Jul 31, 2024: revenue $40.2M (up 6.5% year over year), net income −$5.53M, EPS −$0.09
- Quarter ended Apr 30, 2024 (from the annual report): revenue $43.0M (up 8.0% year over year), net income −$123M, EPS −$1.96
- Quarter ended Jan 31, 2024: revenue $33.8M (down 11.1% year over year), net income −$6.01M, EPS −$0.09
- Quarter ended Oct 31, 2023: revenue $25.4M (down 26.9% year over year), net income −$9.52M, EPS −$0.15
- Quarter ended Jul 31, 2023: revenue $37.7M (up 2.8% year over year), net income −$2.12M, EPS −$0.03
- Quarter ended Apr 30, 2023 (from the annual report): revenue $39.8M (up 27.5% year over year), net income −$335K, EPS −$0.01
- Quarter ended Jan 31, 2023: revenue $38.0M (up 20.7% year over year), net income −$247K, EPS $0.00
- Quarter ended Oct 31, 2022: revenue $34.8M (up 33.1% year over year), net income −$520K, EPS −$0.01
- Quarter ended Jul 31, 2022: revenue $36.7M (up 19.3% year over year), net income $1.36M, EPS $0.02
- Quarter ended Apr 30, 2022 (from the annual report): revenue $31.2M (up 13.1% year over year), net income $116M, EPS $1.64
- Quarter ended Jan 31, 2022: revenue $31.5M, net income $2.25M, EPS $0.04
- Quarter ended Oct 31, 2021: revenue $26.1M, net income $3.52M, EPS $0.06
- Quarter ended Jul 31, 2021: revenue $30.8M, net income $6.30M, EPS $0.10
- Quarter ended Apr 30, 2021: revenue $27.6M, net income $1.99M, EPS −$0.04
CDMO cash flow, buybacks and dividends
- Fiscal year ended Apr 2024: operating cash flow $11.0M, share buybacks n/a
- Fiscal year ended Apr 2023: operating cash flow −$12.7M, share buybacks n/a
- Fiscal year ended Apr 2022: operating cash flow $9.47M, share buybacks n/a
CDMO balance sheet
- Oct 31, 2024: cash $33.4M, total assets $323M, total liabilities $279M, shareholders' equity $44.8M
- Jul 31, 2024: cash $33.4M, total assets $335M, total liabilities $276M, shareholders' equity $58.6M
- Apr 30, 2024: cash $38.1M, total assets $337M, total liabilities $276M, shareholders' equity $60.9M
- Jan 31, 2024: cash $30.7M, total assets $455M, total liabilities $275M, shareholders' equity $180M
- Oct 31, 2023: cash $31.4M, total assets $455M, total liabilities $272M, shareholders' equity $183M
- Jul 31, 2023: cash $24.9M, total assets $443M, total liabilities $253M, shareholders' equity $190M
- Apr 30, 2023: cash $38.5M, total assets $452M, total liabilities $262M, shareholders' equity $189M
- Jan 31, 2023: cash $59.9M, total assets $451M, total liabilities $266M, shareholders' equity $185M
What is CDMO's revenue?
Avid Bioservices Inc reported $150M of revenue over its last four quarters, through October 31, 2024.
Is CDMO profitable?
No. Avid Bioservices Inc lost $152M over the last four quarters.
What is CDMO's EPS?
Diluted earnings per share over the last four quarters were −$2.41; −$0.27 in the latest quarter.